Purpose. This study was done to prepare, characterize, and evaluate salmon calcitonin (sCT) microspheres (ms) in vivo using a low molecular weight, hydrophilic 50:50 poly (D,L-lactide-coglycolide) polymer (PLGA). Methods. sCT ms were prepared by a dispersion/solvent extraction/evaporation process and characterized for drug content, particle size, surface morphology, and structural integrity of encapsulated peptide. Peptide stability and binding to the polymer was studied in 0.1 M phosphate buffer (PB), pH 7.4, and 0.1 M acetate buffer (AB), pH 4.0. Serum sCT levels were monitored for 2 weeks after subcutaneous injection of sCT ms to rats. Results. sCT ms were essentially free of discernible surface pores with a particle size distribution in the range of 16 to 89 mm and mean particle size of 51 and 53 mm for 2 batches. Fourier Transform Matrix-assisted Laser Desorption mass spectrometry of the extracted peptide showed that the encapsulation process did not alter its chemical structure. The peptide was substantially more stable in AB than in PB. Peptide binding to the polymer was dependent on pH and was markedly higher in PB than in AB. In vivo study proved that elevated serum sCT levels could be sustained for at least 10 days after administration of sCT ms to rats at a dose of 1.0 mg/kg. Conclusions. It was demonstrated that sCT could be incorporated into polymeric ms prepared from a low molecular weight, hydrophilic PLGA using a dispersion technique without altering molecular structure. A 2 -week formulation was prepared at a dose of 1.0 mg/kg.
INTRODUCTION
Salmon calcitonin (sCT), a 32 amino acid polypeptide, has a physiological role in the regulation of calcium homeostasis and is a potent inhibitor of bone resorption. Results from clinical trials and animal studies have shown that sCT depresses bone turnover and prevents bone loss in early postmenopausal women [1] [2] [3] and ovariectomized rats [4] [5] [6] . sCT is being used clinically to treat osteoporosis. It is currently formulated as a sterile solution for intramuscular or subcutaneous injection or as a nasal spray. Being a polypeptide, sCT is vulnerable to digestive degradation and has a very short half-life in the body; t 1/2 after parenteral administration is approximately 15 to 20 minutes [7] . The treatment of osteoporosis requires long-term therapy, and because of these properties, which are drawbacks to long-term therapy, patient compliance can be severely limited, especially when a daily injection regimen of sCT is required. Hence, there is an ongoing effort to develop controlled-release dosage forms (formulations) that can effectively deliver sCT.
Poly (D,L lactide-co-glycolide) copolymer (PLGA) has shown promise for the delivery of sCT [8] . This copolymer i s commercially available in a variety of comonomer ratios and molecular weights. Previous work in this laboratory has shown that sCT could be successfully encapsulated with high loading efficiency in PLGA microspheres (ms) made from a high molecular weight, hydrophobic polymer that had end groups protected (alkylated) [ 9] . However, wetting was difficult and required a long time for bond cleavage and biodegradation, and the release of sCT from these ms occurred in intermittent pulses through 120 days, followed by a large peak between 120 and 148 days. 
MATERIALS AND METHODS

Materials
HPLC method for peptide assay
The peptide was analyzed by reverse-phase highperformance liquid chromatography (HPLC) using 2 LC-6A pumps, an SIL-6B autoinjector, an SPD-6AV detector, and an SCL-6B system controller (all from Shimadzu Scientific Instruments, Inc, Columbia, MD). The column used was a Bondclone 10, C-18 reversed-phase column (150 × 3.90 mm) with a Bondclone 10, C-18 (30 × 3.90 mm) guard column (Phenomenex, Torrance, CA). Gradient elution was accomplished with 0.1% trifluoroacetic acid in water (A) and acetonitrile, 0.1% trifluoroacetic acid (B) and increasing the amount of phase B from 30% to 50% over 10 minutes at a flow of 1.5 mL/min. Standard curves of sCT ranging from 6.25 to 200 µg/mL yielded linear responses over that concentration range with detection at 220 nm.
Polymer Characterization
The molecular weight distribution of RG502H PLGA polymer was determined by gel permeation chromatography (GPC) using a Waters M-45 solvent delivery system with a Waters 990 Photodiode Array Detector and ultrastyragel columns connected in series (7.8 × 300 mm each, one with 10 4 Å pores and one with 10 3 Å pores). The polymer was dissolved in tetrahydrofuran (THF) at 0.1% (wt/vol), eluted with THF at 1 mL/min and analyzed at 230 nm. Number average molecular weight (M n ), weight average molecular weight (M w ), and polydispersity (M w /M n ) were determined.
T g was determined using a differential scanning calorimeter (DSC) equipped with a refrigeration system (Thermal Analysis Instruments DSC 2920, New Castle, DE). From 5 to 10 mg of the polymer was sealed in an aluminum pan. Then, under a nitrogen purge, the sample and reference (empty pan) were heated at a rate of 5ºC min -1 from 20ºC to 80ºC, cooled at 10ºC min -1 to 20ºC, then heated at 5ºC min -1 to 65ºC.
Preparation of sCT ms
sCT ms were prepared by a dispersion method followed by solvent extraction and evaporation.
Briefly . The temperature of the reactor was maintained initially at 25ºC for 30 minutes and then at 35ºC for 3 hours. Once ms were formed and hardened, the contents of the reactor were transferred to a filtration apparatus equipped with a 0.8 µ membrane filter (Gelman Sciences, Ann Arbor, MI), and the recovered product was rinsed with water and either lyophilized or dried under reduced pressure for 48 hours at room temperature. Blank ms, without sCT, were prepared similarly.
Microsphere Characterization
Peptide content in ms was determined by HPLC after dissolving the ms in methylene chloride and extracting the peptide with 0.1 M acetate buffer (AB), pH 4.0. Fourier Transform Matrix-assisted Laser Desorption (FT-MALDI) mass spectrometry with dihydrobenzene as the matrix and nitrogen laser at 260° intensity was used to determine the molecular weight of sCT. The integrity of encapsulated sCT was confirmed by comparing the mass spectrum of sCT extracted from the ms to that of standard sCT solution.
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The glass transition temperature of ms was determined by DSC. Particle size distribution was determined using a laser diffraction technique (Malvern 2600c Particle Sizer, Malvern, UK). Surface morphology was analyzed by scanning electron microscopy (SEM) with a Hitachi S 800 (Tokyo, Japan) instrument after palladium/gold coating on aluminum stubs. Total product yield was assessed gravimetrically on the basis of polymer/drug recovery.
IN VITRO STUDIES
Peptide Stability
Stock solutions of sCT were prepared by dissolving 10 mg of sCT in 50 mL of 0.1 M phosphate buffer (PB), pH 7.4, or 0.1 M AB, pH 4.0. All solutions were used immediately upon preparation. Peptide stability was determined in PB and AB at 3 temperatures: 4ºC, 25ºC, and 37°C. Approximately 5 mL of fresh stock solutions were placed in 7 mL glass scintillation vials, and the vials were sealed. Periodically, aliquots were removed from each vial, and the amount of intact peptide was assayed by HPLC.
Peptide Adsorption to PLGA ms
Stock solutions of sCT were prepared by dissolving 15 mg of sCT in 30 mL of 0.1 M PB, pH 7.4, or 0.1 M AB, pH 4.0. All solutions were used immediately upon preparation. O ne milliliter of sCT stock solutions in PB and AB were incubated at 37°C with 10 mg of blank ms. At each time point, 2 samples of each suspension were removed from the incubator. The samples were centrifuged, and the amount of peptide in the supernatant was determined by HPLC.
In Vivo Evaluation of sCT ms
sCT ms were evaluated in vivo in female SpragueDawley rats. Three groups of rats were subjected to the treatments described in Table 1 . Free sCT was dissolved in 0.9% saline, and a single injection was administered subcutaneously at a dose of 71 µg/kg. The microsphere lots were suspended in a mixture of 1% CMC and 2% mannitol. The formulations were injected at point body weight volume (ie, µL administered = g body weight) subcutaneously, just below the neck region. A single injection was given to each animal immediately after collecting a predosing sample.
Blood samples were collected from the tail vein under light ether anesthesia. Samples from the animals receiving free sCT were collected at 0, 1, 6, and 24 hours after injection. Samples from the animals receiving the microsphere formulations at 0.5 mg/kg and 1.0 mg/kg doses were collected at 0, 1 hour, and 1, 3, 6, 9, 12, and 15 days after injection. The samples were centrifuged in Microtainer tubes (Becton Dickinson, Franklin Lakes, NJ) to separate and collect the serum. Serum samples were frozen and stored at -20°C until analysis using a radioimmunoassay (RIA).
Serum sCT analysis
Serum sCT was measured by 125 I RIA with a commercially available kit (Peninsula Laboratories, San Carlos, CA). Serum samples were incubated with rabbit sCT antiserum for 24 hours at 4°C followed by addition of 125 I-labeled sCT. After an additional 24-hour incubation, a second antibody-goat antirabbit immunoglobulin G -was added, followed by 90-minute incubation at room temperature to separate the antibody-bound and free sCT. The antibody-bound radioactivity was then measured by a MINAXI gcounter (Packard, Downers Grove, IL).
RESULTS
Polymer Characterization
The M w and M n of RG502H were approximately 7800 and 4500 d, respectively (polydispersity 1.8). RG502H showed a T g of 36.4°C.
Microsphere Characterization
Thermal analysis of blank ms prepared from RG502H polymer showed an increase in T g (39.5°C) compared to that of the raw polymer. However, the T g of the 2 lots of sCT ms, sCT01 and sCT02 (40.5°C and 40.3°C, respectively), was not much different than that of the blank ms ( Table 2) . sCT indicates salmon calcitonin.
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The average particle size of the 2 lots of sCT ms was 53 (sCT01) and 51 (sCT02) mm. Incorporation efficiencies of 102% and 90% revealed that most of the sCT had been encapsulated within the ms. Examination of the surface morphology by SEM revealed that both sCT as well as blank ms were free of discernible surface pores ( Figure 1 ). The mass spectrum of sCT extracted from ms ( Figure 4 shows the effect of pH and temperature on the stability of sCT in solution. The peptide was substantially more stable in AB, pH 4.0, than in PB, pH 7.4. In PB at 37°C, 37% of the peptide was degraded within 24 hours and 100% after 3 days. In AB at 37°C, 95% of the initial amount still remained after 3 days, 90% after 6 days, 71% after 15 days, and 63% after 22 days. Peptide degradation was slower at lower temperatures in both buffers, and as much as 82% and 91% of the initial amount still remained after 22 days at 22°C and 4°C, respectively, in AB. A. Blank ms B. sCT01 ms C. sCT02 ms 
Peptide Stability
Peptide Adsorption to PLGA ms
As shown in Figure 5 , there was not much adsorption of sCT to blank PLGA ms in 0.1 M AB, pH 4.0, at 37°C, and the amount of peptide remaining in the supernatant throughout 24 hours was 97% ± 2% of the initial amount. In contrast, the amount of peptide adsorbed to the blank ms in 0.1 M PB, pH 7.4, increased with time, and approximately 19.7 µg of peptide was adsorbed to 1 mg of ms after 5 hours (41% of the initial amount). Although no samples were analyzed between 6 and 24 hours, saturation binding appeared to occur within 24 hours at approximately 20 µg/mg. 
In Vivo Study
Single administration of free sCT to rats at 71 µg/kg dose ( Figure 6A ) resulted in a serum sCT peak 1 hour later (observed C max 760 pg/mL). As expected, the sCT levels returned rapidly to baseline levels at 24 hours, since sCT has a very short half-life in vivo after parenteral administration [ 7] . Administration of 0.5 mg/kg dose of sCT microspheres ( Figure 6B ) resulted in a C max of 791 pg/mL at 1 hour. Elevated serum sCT levels were sustained for at least 6 days, and 6 detectable levels were observed for 9 days following administration. Administration of 1.0 mg/kg dose of sCT microspheres produced a C max of 984 pg/ml at 1 hour ( Figure 6C ), and elevated serum sCT levels were sustained beyond 9 days after administration, with the levels returning to baseline after 12 days.
DISCUSSION
GPC analysis of the raw 502H polymer showed that the M w was 7800 d. This was lower than the typical 502H lots, which have M w in the range of 10 000 d. This would account for the shorter duration of elevated serum levels than desired. DSC measurements indicated that the blank ms prepared from 502H polymer had a slightly higher T g (39.5°C) than did the raw polymer (36.4°C). This slight shift in T g was most likely the result of the processing of the polymer during the microsphere preparation process. On the other hand, T g of sCT ms (40.3°C and 40.5°C) was comparable to blank ms. A marked shift in T g would have indicated a strong interaction between sCT and the polymer (in the dry state). Thus, the DSC results suggest that in the dry state, sCT did not interact very strongly with the hydrophilic, low molecular weight 502H PLGA polymer. A higher molecular weight 502H polymer would have a slightly higher T g , which would facilitate processing.
FT-MALDI mass spectrum of the extracted peptide showed that the encapsulation process did not alter its chemical structure. Stability studies confirmed that the peptide was substantially more stable in solution at a pH of 4.0 than at a pH of 7.4, which was consistent with previous studies that had reported a pH of 3.3 for maximum stability [ 10] . There was very little adsorption of sCT to blank PLGA ms at a pH of 4.0. However, the adsorption increased dramatically at a pH of 7.4. These results indicate that the nonspecific adsorption of sCT to PLGA ms was greater at a pH closer to the isoelectric point (pI) of sCT, which is around 10.2 [11] . This is consistent with earlier work on sCT adsorption to a higher molecular weight PLGA (M W 34 000) containing alkylated (hydrophobic) end groups, where maximum adsorption occurred near the pI of sCT and almost no adsorption was observed at a pH less than 6 [11] . It was thought that a higher net charge on the peptide molecules, at a pH below pI, could result in repulsion within and between peptide molecules. At the pI of the peptide, molecules with a zero net charge could approach each other more closely and form a more compact conformation, resulting in more effective adsorption. The results of that study suggested that hydrophobic interactions played an important role in the adsorption. Interestingly, at pH 7.4, the amount of sCT adsorbed to the low molecular weight (hydrophilic) PLGA (502H) was much lower (19.7 µg sCT/mg PLGA) compared with the high molecular weight (hydrophobic) PLGA (>80 µg sCT/mg PLGA) [11] . Because elevated serum sCT levels could be sustained for about 10 days following administration of sCT ms to rats at a dose of 1.0 mg/kg, this was thought to be promising as a 2-week formulation, especially with a higher molecular weight 502H PLGA.
CONCLUSIONS
It was demonstrated that sCT could be incorporated into polymeric ms prepared from a low molecular weight, hydrophilic PLGA with the dispersion technique without altering its molecular structure. DSC measurements indicated a lack of strong interaction between sCT and the polymer in the dry state. Peptide stability was greater at lower pH, while binding was significantly higher at higher pH. Elevated serum sCT levels could be sustained for at least 10 days following administration of 1.0 mg/kg of sCT ms to rats.
